Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455306 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL6561558 | 0.79 | KMT2A (0.58) | LMNAKMT2AMEN1 | |
| SCHEMBL4212055 | 0.78 | POLB (0.77) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL417886 | 0.77 | MEN1 (0.72) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL3454904 | 0.74 | POLB (0.69) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL1548100 | 0.73 | SPHK2 (0.69) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL4206459 | 0.73 | MEN1 (0.59) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL14651319 | 0.73 | MEN1 (0.66) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL24273864 | 0.72 | KMT2A (0.72) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL11545749 | 0.72 | MEN1 (0.62) | LMNASMN1; SMN2POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | LMNA 4109/4885SMN1; SMN2 4780/4885POLB 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.